SUBSCRIBE
SUBSCRIBE
News   Drug Development

Protalix Biotherapeutics, Inc. Plans Human Clinical Tests of Medication for Rare Fabry’s Disease

March 24, 2011 | 
1 min read
Bloomberg -- Protalix BioTherapeutics Ltd., an Israeli biotechnology company, plans to start clinical trials of a drug treating Fabry disease this year and a medication against rheumatoid arthritis in early 2012.
Preclinical
MORE ON THIS TOPIC
Abstract creative art collage, market declines in the stock market. The concept of collapse or bankruptcy.
Obesity
Rhythm’s Imcivree Fails Late-Stage Weight Loss Trial in Rare Obesities
March 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Symbolic image: Life as a hurdling - person faces challenges
Insights
AI Drug Discovery Platforms Face New Investor Bar
March 17, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Rare diseases
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal
March 16, 2026
 · 
2 min read
 · 
Heather McKenzie
Art collage with male hand and graphs. Concept of business, finance, economy, professionalism and success. Symbolism and surrealism. Copy space.
Obesity
Structure Climbs on ‘Highly Competitive’ Profile for Weight Loss Pill
March 16, 2026
 · 
2 min read
 · 
Tristan Manalac